In:
Oncology, S. Karger AG, Vol. 72, No. 5-6 ( 2007), p. 308-313
Abstract:
〈 i 〉 Background: 〈 /i 〉 Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging. Effective and well-tolerated regimens are required. Gemcitabine plus capecitabine combination was assessed in MBC patients pretreated with anthracyclines and taxanes. 〈 i 〉 Patients and Methods: 〈 /i 〉 A total of 31 patients treated between November 2004 and September 2005 were retrospectively evaluated in 4 institutions. The median age was 48 years (range 29–77). The patients were given gemcitabine 1,000 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1 and 8, and capecitabine 1,500 mg/m 〈 sup 〉 2 〈 /sup 〉 twice daily on days 1–14 every 3 weeks. 〈 i 〉 Results: 〈 /i 〉 A total of 160 cycles of chemotherapy were administered with a median of 5 cycles per patient (range 2–12). Three patients achieved a partial response (10%) and 8 patients (26%) stable disease. The median time to disease progression was 6 months (95% CI 5–7), with a median survival of 18 months (95% CI 15–21) at a median follow-up of 16 months (range 2–28). One-year and 2-year survival rates were 67 and 28%, respectively. Grade 3–4 toxicities were as follows: neutropenia (n = 11, 35%), nausea and vomiting (n = 4, 13%), hand-foot syndrome (n = 2, 6%), anemia (n = 2, 6%), thrombocytopenia (n = 2, 6%) and asthenia (n = 1, 3%). 〈 i 〉 Conclusion: 〈 /i 〉 The combination of gemcitabine plus capecitabine was a tolerable regimen with a mild but comparable survival efficacy to similar regimens in patients with MBC after anthracyclines and taxanes.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2007
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink
